MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/s0006-3223(02)01971-6

Медицинская библиотека · Biological psychiatry · 2003

Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression.

Gelenberg Alan J, Trivedi Madhukar H, Rush A John, Thase Michael E, Howland Robert, Klein Daniel N, Kornstein Susan G, Dunner David L, Markowitz John C, Hirschfeld Robert M A, Keitner Gabor I, Zajecka John, Kocsis James H, Russell James M, Miller Ivan, Manber Rachel, Arnow Bruce, Rothbaum Barbara, Munsaka Melvin, Banks Phillip, Borian Frances E, Keller Martin B

Клиническое исследованиеСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Maintenance treatment to prevent recurrences is recommended for chronic forms of major depressive disorder (MDD), but few studies have examined maintenance efficacy of antidepressants with chronic MDD. This randomized, placebo-controlled study of the efficacy and safety of nefazodone in preventing recurrence was conducted for patients with chronic MDD.

METHODS

A total of 165 outpatients with chronic, nonpsychotic MDD, MDD plus dysthymic disorder ("double-depression"), or recurrent MDD with incomplete inter-episode recovery, who achieved and maintained a clinical response during acute and continuation treatment with either nefazodone alone or nefazodone combined with psychotherapy, were randomized to 52 weeks of double-blind nefazodone (maximum dose 600 mg/day) or placebo. The occurrence of major depressive episodes during maintenance treatment was assessed with the 24-item Hamilton Rating Scale for Depression, a DSM-IV MDD checklist, and a blinded review of symptom exacerbations by a consensus committee of research clinicians.

RESULTS

Application of a competing-risk model that estimated the conditional probability of recurrence among those patients remaining on active therapy revealed a significant (p =.043) difference between nefazodone (n = 76) and placebo (n = 74) when the latter part of the 1-year maintenance period was emphasized. At the end of 1 year, the conditional probability of recurrence was 30.3% for nefazodone-treated patients, compared with 47.5% for placebo-treated patients. Prior concomitant psychotherapy during acute/continuation treatment, although enhancing the initial response, was not associated with lower recurrence rates. Discontinuations due to adverse events were relatively low for both nefazodone (5.3%) and placebo (4.8%). Somnolence was significantly greater among the patients taking active medication (15.4%), compared with placebo (4.6%).

CONCLUSIONS

Nefazodone is well-tolerated and is an effective maintenance therapy for chronic forms of MDD.

Для цитирования: Gelenberg Alan J, Trivedi Madhukar H, Rush A John, Thase Michael E, Howland Robert, Klein Daniel N, Kornstein Susan G, Dunner David L, Markowitz John C, Hirschfeld Robert M A, Keitner Gabor I, Zajecka John, Kocsis James H, Russell James M, Miller Ivan, Manber Rachel, Arnow Bruce, Rothbaum Barbara, Munsaka Melvin, Banks Phillip, Borian Frances E, Keller Martin B. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression.. Biological psychiatry. 2003. DOI: 10.1016/s0006-3223(02)01971-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.